Skip to main content
. 2017 Sep 30;36(3):257–263. doi: 10.23876/j.krcp.2017.36.3.257

Figure 2.

Figure 2

Relapse rates (mean ± 95% confidence interval) of nephrotic syndrome before and after rituximab (RTX) treatment.